U.S. Markets close in 2 hrs 25 mins

Cassava Sciences, Inc. (SAVA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
7.50+0.19 (+2.58%)
As of 1:34PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close7.31
Bid7.51 x 1800
Ask7.52 x 800
Day's Range7.22 - 7.56
52 Week Range1.51 - 12.68
Avg. Volume8,454,601
Market Cap262.111M
Beta (5Y Monthly)1.89
PE Ratio (TTM)N/A
EPS (TTM)-0.23
Earnings DateNov 09, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateDec 13, 2012
1y Target Est19.33
  • USAN Modifies Lead Drug Candidate’s Chemical Name to ‘Simufilam’

    USAN Modifies Lead Drug Candidate’s Chemical Name to ‘Simufilam’

    Future References to Lead Drug Candidate for Alzheimer’s Disease Will Be SimufilamAUSTIN, Texas, Nov. 27, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today announced that the World Health Organization (WHO) advised the United States Adopted Names Council (USAN) to modify the chemical name of the Company’s lead drug candidate to ‘simufilam.’ This change was advised by WHO to avoid a potential trademark conflict with a drug marketed in the Far East. USAN has accepted WHO’s advice. Future references to Cassava Sciences’ lead drug candidate for Alzheimer’s disease will be simufilam.About USAN The United States Adopted Names Council is responsible for selecting simple, informative and unique nonproprietary drug names. The USAN Council establishes logical nomenclature classifications based on pharmacological or chemical relationships. In addition to one member-at-large and a U.S. Food and Drug Administration liaison, USAN consists of one representative from The American Medical Association, the United States Pharmacopeia and the American Pharmacists Association.About Alzheimer's Disease Alzheimer’s disease is a progressive brain disorder that destroys memory and thinking skills. Currently, there are no drug therapies to halt Alzheimer’s disease, much less reverse its course. In the U.S. alone, approximately 5.8 million people are currently living with Alzheimer’s disease, and approximately 487,000 people age 65 or older developed Alzheimer’s in 2019. The number of people living with Alzheimer’s disease is expected to grow dramatically in the years ahead, resulting in a growing social and economic burden.About Simufilam Simufilam is Cassava Sciences’ lead therapeutic product candidate for the treatment of Alzheimer’s disease. Simufilam is a proprietary, small molecule (oral) drug that restores the normal shape and function of altered filamin A (FLNA), a scaffolding protein, in the brain. Altered FLNA in the brain disrupts the normal function of neurons, leading to Alzheimer’s pathology, neurodegeneration and neuroinflammation. The underlying science is published in peer-reviewed scientific journals, including Journal of Neuroscience, Neurobiology of Aging, Journal of Biological Chemistry, Neuroimmunology and Neuroinflammation and Journal of Prevention of Alzheimer’s Disease.About Cassava Sciences, Inc. Cassava Sciences’ mission is to discover and develop innovations for chronic, neurodegenerative conditions. Over the past 10 years, Cassava Sciences has combined state-of-the-art technology with new insights in neurobiology to develop novel solutions for Alzheimer’s disease. For more information, please visit: https://www.CassavaSciences.comFor More Information Contact: Eric Schoen, Chief Financial Officer Cassava Sciences, Inc. eschoen@CassavaSciences.com (512) 501-2450

  • Pacira (PCRX) Gets European Commission Approval for Exparel

    Pacira (PCRX) Gets European Commission Approval for Exparel

    The EC approves Pacira's (PCRX) Exparel for treating post-operative pain in adults and as a field block for treating somatic post-operative pain from small- to medium-sized surgical wounds in adults.

  • 3 Best Biotech Stocks to Buy in November
    Motley Fool

    3 Best Biotech Stocks to Buy in November

    While most investors are watching the companies working to end the COVID-19 crisis, take a moment to consider three that are continuing the fight against an even more stubborn disease.